Contra-indicated in patients with active pathological bleeding.
- Trade Name: Bevyxxa (Portola)
- Indications: Prophylaxis of venous thromboembolism in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications
- Class: Direct factor Xa inhibitor
- Half-life: 19–27 hours
- FDA Approval Date: 06/23/2017
- Clinically important, potentially hazardous interactions with:
Amiodarone, Anticoagulants, antiplatelet drugs and thrombolytics, Azithromycin, Clarithromycin, Ketoconazole, Verapamil - Pregnancy: Likely to increase the risk of hemorrhage during pregnancy and delivery
- See adverse reactions attributed to class:
SPINAL/EPIDURAL HEMATOMA
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
